Rybelsus arrived in 2019 with strict fasting rules that a 2026 rival pill avoided

The FDA approved Rybelsus (semaglutide) on September 20, 2019, making it the first oral GLP-1 treatment for adults with type 2 diabetes ^[1][2]. The daily tablet came with instructions that later became a basis for comparison with competing oral pills: it had to be taken on an empty stomach with no more than 4 ounces of plain water, followed by a 30-minute wait before eating, drinking or taking other oral medicines ^[1].

Rybelsus contains semaglutide, the same molecule used in Ozempic injection, first approved December 5, 2017, and in Wegovy, approved June 4, 2021 ^[2]. The tablet is indicated as an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes, and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes who are at high risk for those events ^[2]. Its most common side effects, occurring in 5% or more of patients, are nausea, abdominal pain, diarrhea, decreased appetite, vomiting and constipation ^[2]. Warnings listed on the label include acute pancreatitis, diabetic retinopathy complications, low blood sugar when used with insulin or insulin secretagogues, acute kidney injury from dehydration, severe gastrointestinal reactions, hypersensitivity reactions, and pulmonary aspiration during general anesthesia or deep sedation ^[2].

The fasting rules follow from the drug's chemistry. Oral semaglutide is peptide-based and is co-formulated with an absorption enhancer called salcaprozate sodium (SNAC) ^[1]. Only about 0.4% to 1% of each oral semaglutide dose is absorbed under optimal conditions, and food or beverages other than a small volume of plain water substantially reduce that absorption ^[1].

That limitation shaped how a later oral GLP-1 was described. On April 1, 2026, the FDA approved orforglipron (Foundayo) for chronic weight management in adults with obesity, or in adults who are overweight with at least one weight-related condition ^[1]. Orforglipron is a small-molecule, nonpeptide GLP-1 receptor agonist that can be taken at any time of day with or without food ^[1]. Its approval is for weight management; a type 2 diabetes approval has not yet been granted, and Lilly has said a US submission for that use is planned ^[1].

In the ATTAIN-1 trial, 3,127 adults without diabetes took once-daily orforglipron at 6 mg, 12 mg or 36 mg, or a placebo, for 72 weeks ^[1]. Average body weight change was −7.5% at 6 mg, −8.4% at 12 mg and −11.2% at 36 mg, compared with −2.1% for placebo ^[1]. Under a separate analysis that estimated outcomes had all participants stayed on treatment, the 36 mg group lost an average of 27.3 lb (12.4%), compared with 2.2 lb (0.9%) for placebo ^[1]. Among participants on 36 mg, 54.6% lost at least 10% of body weight, 36.0% lost at least 15% and 18.4% lost at least 20% ^[1]. Side effects led 5.3% to 10.3% of orforglipron participants to stop treatment, versus 2.7% on placebo, with gastrointestinal effects most common ^[1].

Rybelsus labeling has changed since 2019. An R2 formulation was approved December 9, 2024, and on January 30, 2026, the FDA approved relabeling that formulation as Ozempic (semaglutide) tablets ^[2]. Wegovy tablets were approved December 22, 2025 ^[2]. Ozempic tablets were expected to reach US pharmacies in the second quarter of 2026 ^[2].

Why it matters for patients

For people taking oral semaglutide, the timing instructions are part of how the medicine works. Taking the tablet with food or with more than a small amount of water reduces how much semaglutide is absorbed, which is why the label specifies an empty stomach, no more than 4 ounces of plain water, and a 30-minute wait ^[1]. In practice, that means no morning coffee or other oral medicines during that window ^[1].

Orforglipron removes that scheduling step but is not a like-for-like substitute. It is approved for weight management rather than type 2 diabetes, and it carries a boxed warning for thyroid C-cell tumors, including medullary thyroid carcinoma, consistent with the class warning shared by GLP-1 medicines ^[1]. It is also not recommended for use with another GLP-1 medicine ^[1].

Cost and access differ as well. Eligible patients with commercial insurance may pay as little as $25 per month for orforglipron with a Lilly savings card, self-pay pricing starts at $149 per month for the lowest dose, and eligible Medicare Part D beneficiaries may access it for $50 per month beginning July 1, 2026 ^[1]. Rybelsus pricing is not detailed in the same materials ^[2]. Fewer than 1 in 10 people who could benefit from a GLP-1 medicine are currently taking one, according to Lilly chair and CEO David A. Ricks, who cited access barriers, stigma and the perception that the condition is not serious enough to treat ^[1].

What happens next

Medicare Part D coverage for eligible orforglipron patients begins July 1, 2026, at $50 per month ^[1]. A US regulatory submission for orforglipron in type 2 diabetes is planned, though a filing date has not been disclosed ^[1]. Orforglipron is also being studied for obstructive sleep apnea, osteoarthritis knee pain, hypertension, peripheral artery disease and stress urinary incontinence ^[1].